Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on molecular glue degrader (MGD)-based medicines, announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat on June 4, 2025, at 12:50 p.m. EDT. The presentation will be available through webcast on the company's investor relations website, with a replay accessible for 30 days afterward.
Monte Rosa Therapeutics (Nasdaq: GLUE), un'azienda biotecnologica in fase clinica specializzata in farmaci basati su degradatori a colla molecolare (MGD), ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il CEO Markus Warmuth parteciperà a una conversazione informale il 4 giugno 2025 alle 12:50 EDT. La presentazione sarà disponibile in webcast sul sito web per gli investitori dell'azienda, con una replica accessibile per 30 giorni successivi.
Monte Rosa Therapeutics (Nasdaq: GLUE), una empresa biotecnológica en etapa clínica enfocada en medicamentos basados en degradadores de pegamento molecular (MGD), anunció su participación en la próxima Conferencia Global de Salud Jefferies. El CEO Markus Warmuth participará en una charla informal el 4 de junio de 2025 a las 12:50 p.m. EDT. La presentación estará disponible en webcast en el sitio web de relaciones con inversores de la compañía, con una repetición accesible durante 30 días después.
Monte Rosa Therapeutics(나스닥: GLUE)는 분자 접착제 분해제(MGD) 기반 의약품에 주력하는 임상 단계 생명공학 기업으로, 다가오는 Jefferies 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO Markus Warmuth는 2025년 6월 4일 오후 12시 50분 EDT에 파이어사이드 챗에 참석할 예정입니다. 발표는 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 이후 30일간 다시보기로 이용할 수 있습니다.
Monte Rosa Therapeutics (Nasdaq : GLUE), une société biotechnologique en phase clinique spécialisée dans les médicaments à base de dégradeurs colle moléculaire (MGD), a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le PDG Markus Warmuth participera à une discussion informelle le 4 juin 2025 à 12h50 EDT. La présentation sera disponible en webcast sur le site des relations investisseurs de la société, avec un replay accessible pendant 30 jours ensuite.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Medikamente auf Basis von molekularen Klebstoff-Degradatoren (MGD) spezialisiert hat, gab seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference bekannt. CEO Markus Warmuth wird am 4. Juni 2025 um 12:50 Uhr EDT an einem Fireside-Chat teilnehmen. Die Präsentation wird per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit einer Wiedergabe, die 30 Tage lang abrufbar ist.
- None.
- None.
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT.
A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans autoimmune and inflammatory diseases, oncology, and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the Jefferies Healthcare Conference 2025?
Who will represent Monte Rosa Therapeutics (GLUE) at the Jefferies Conference 2025?
How can investors access Monte Rosa Therapeutics' (GLUE) Jefferies Conference presentation?
What is Monte Rosa Therapeutics' (GLUE) main business focus?
